Getting a biopsy is one of those medical experiences that sounds simple until you’re living it. A needle goes in, a small amount of tissue is collected, and a pathologist determines whether something is wrong. Quick, routine, effective – in theory.
In practice, biopsies fail more often than most patients realize. Up to a third of tissue samples come back with too little material to make a confident diagnosis. When that happens, everything stalls: you wait longer, you go back for another procedure, you sit with uncertainty while a doctor tries again. For cancer patients, that delay can have real consequences.
A research team from Aalto University and the University of Helsinki has been working on a quiet fix to this longstanding problem – and their first human clinical trial results, published in April 2026 in European Radiology Experimental, are encouraging. The solution involves a biopsy needle that vibrates at ultrasonic frequency, collecting significantly more tissue with the same small puncture wound – and without compromising sample quality.
The Problem With Getting Enough Tissue
To understand why this matters, it helps to understand the two main types of needle biopsy used today.
The first is called fine-needle aspiration biopsy (FNAB). It’s minimally invasive – the needle is thin, the wound is tiny, and the procedure is fast. The drawback is that it often collects a frustratingly small amount of material. Pathologists sometimes get barely enough cells to work with, and a significant proportion of FNAB samples are simply classified as “inadequate” – meaning no diagnosis is possible from that sample alone.
The second is core needle biopsy (CNB). This approach uses a thicker needle that extracts a more substantial chunk of tissue, yielding much better material for analysis. But the larger needle means a more invasive procedure, greater discomfort for the patient, and a higher risk of bleeding or other complications.
Doctors have been stuck choosing between these two imperfect options for decades. The Finnish research team asked: what if you could get core-needle quality tissue with a fine needle?
The Vibrating Needle: How It Works
The new device is called the ultrasound-enhanced fine-needle aspiration biopsy tool, or USeFNAB. Its key innovation is built directly into the needle tip: a component that creates what engineers call flexural ultrasonic actuation, causing the tip to oscillate sideways at roughly 30 kilohertz – that’s approximately 30,000 vibrations per second, far beyond what the human ear can detect and far faster than any manual hand movement.
Those rapid, tiny vibrations change the physics of what happens when a needle meets tissue. Normally, collecting a useful sample requires the needle to mechanically shear and cut its way through cells. The amount collected depends heavily on how far the needle travels and how aggressively it’s manipulated. With USeFNAB, the ultrasonic oscillations at the tip create additional mechanical forces – shear, compression, and tension – that help tissue detach from surrounding structures and move into the needle lumen more efficiently.
Think of it as the difference between pressing a dull knife slowly through a block of cheese versus using a vibrating slicer. The cut is cleaner, the yield is better, and you don’t need to apply nearly as much force to get what you need.
“In a clinical setting, such improvements could potentially offer more confident diagnostic conclusions through the sample being better representative of the sampled target and reduce the need for repeat biopsies, optimizing both radiological and clinical workflow, and patient experience.”— Research team, Aalto University / University of Helsinki, European Radiology Experimental, 2026
What the Clinical Trial Showed
The study was a first-in-human pilot trial involving ten adult patients with solid benign parotid gland tumors – non-cancerous growths in the salivary glands near the jaw. Each patient was already scheduled for surgery, which meant the team had a rare opportunity: they could try all three biopsy techniques on the same tumor before the operation, then compare the results directly against the actual excised tissue analyzed by a blinded pathologist.
The results were clear. USeFNAB produced histological samples between 1.7 and 3.4 times larger than standard FNAB, and the tissue mass collected was 1.6 to 3.4 times greater than core needle biopsy. Critically, quality wasn’t sacrificed for quantity – the samples maintained adequate tissue architecture for proper pathological assessment.
| 3.4× More tissue than standard fine-needle biopsy (FNAB) | 3.4× More tissue than core needle biopsy (CNB) | ~30k Vibrations per second at the needle tip |
Perhaps most importantly for patients: all of that was achieved without enlarging the puncture wound. The needle remained fine-gauge. The tool simply used the same small opening more efficiently.
The researchers also noted that prior lab studies using animal and human tissue samples ex vivo had suggested USeFNAB could collect 2 to 6 times more tissue than standard techniques. The human trial confirmed that the gains translate to real patients in real clinical settings — a hurdle that many promising technologies fail to clear.
Why Inadequate Biopsies Are Such a Big Problem
It’s worth pausing to appreciate the scale of what inadequate biopsy samples actually cost – in time, anxiety, and clinical risk.
The Hidden Cost of Insufficient Samples
- Up to 34% of histological (tissue) biopsies yield diagnostically insufficient material
- Up to 50% of molecular assessments fail due to inadequate cell counts
- Failed biopsies mean repeat procedures – more patient discomfort, more appointments, more waiting
- Time pressure to begin cancer treatment can force decisions made with incomplete information
- Delays between biopsy and diagnosis directly affect patient outcomes in fast-growing cancers
When a biopsy comes back inadequate, it doesn’t just mean inconvenience. In the context of a possible cancer diagnosis, it can mean starting treatment without a full picture, delaying treatment while waiting for a second sample, or misidentifying the nature of a tumor. The diagnostic gap created by insufficient tissue is a real and underappreciated clinical problem – and it’s one that has persisted largely because the tools haven’t changed much in decades.
This is where USeFNAB’s potential goes beyond the numbers. A 3x improvement in tissue yield doesn’t just mean a better sample – it potentially means a first-attempt success in cases that would previously have required a second or third procedure. For patients, that’s fewer hospital visits. For radiologists, it’s better workflow. For the healthcare system, it’s lower cost and faster throughput.
What Comes Next: Thyroid, Breast, and Beyond
The pilot study focused on parotid gland tumors specifically because of the timing opportunity created by scheduled surgeries. But the research team is clear that the technology isn’t limited to salivary gland tissue. The next planned studies will test USeFNAB in thyroid and breast tumors – two of the most common biopsy targets in clinical medicine.
Thyroid nodules are extraordinarily common. Many are benign, but distinguishing benign from malignant nodules requires biopsy, and fine-needle aspiration is the standard approach. FNAB of thyroid nodules has a well-documented inadequacy rate – meaning a substantial proportion of patients need to come back for a repeat procedure. A tool that reliably collects more material on the first pass would have immediate, tangible impact on how thyroid disease is managed.
Breast biopsies present a similar picture. Ultrasound-guided biopsy is a cornerstone of breast cancer diagnosis, and the push toward less-invasive procedures – moving away from core needle where possible – has been ongoing. A fine needle that performs at core-needle levels would change the calculus significantly.
“We’re excited about exploring the many possibilities. The clear goal is to improve patient care.”— Katri Aro, researcher, University of Helsinki
The Ultrasound Connection: More Than Just Imaging
There’s a broader story here worth noticing. Ultrasound is quietly undergoing a transformation from a diagnostic imaging tool into an active therapeutic and procedural platform. We’re seeing it used to deliver drugs across the blood-brain barrier, to ablate tumors, to create light inside tissue (as covered in our previous post), and now to dramatically improve the mechanical performance of biopsy needles.
What makes all of these applications possible is a fundamental property that makes ultrasound uniquely valuable in medicine: sound waves interact with tissue in ways that are controllable, targetable, and safe at appropriate frequencies and intensities. The same physics that lets ultrasound bounce off a gallbladder to create an image can, at different parameters, cause tissue to move, heat up, cavitate, or – in the case of USeFNAB – release from surrounding structures and enter a collection needle.
This is why ultrasound-based diagnostics and screening are at the center of modern early detection medicine, and why the technology continues to open new clinical possibilities at a pace that few other imaging modalities can match. The fact that it’s non-ionizing – no radiation, no lasting biological effect at diagnostic levels – makes it a platform that can be extended into more sensitive populations and more frequent screening protocols than X-ray or CT-based approaches.
For patients undergoing preventive health screenings – especially those in higher-risk populations like first responders or individuals with family histories of cancer – the pipeline from screening to diagnosis to treatment is critically important. A technology that reduces the friction and failure rate in the diagnostic step of that pipeline isn’t just a technical improvement. It’s a patient experience improvement, and potentially a life-saving one.
Putting It in Context: Still a Pilot Study
Ten patients is a small cohort. The researchers are candid about this – the study is explicitly labeled a pilot, and its purpose was to establish feasibility and safety in humans, not to generate statistically definitive efficacy data. The results are promising, but the next steps involve larger multi-center trials across different tumor types before USeFNAB could realistically enter widespread clinical use.
That said, the foundational science here is solid. Prior lab studies across multiple tissue types have consistently shown the tissue yield advantage, and the first human trial confirmed those gains hold up in vivo. The regulatory and commercialization path for a device like this – essentially a modified biopsy needle with an integrated piezoelectric actuator – is generally more straightforward than for a pharmaceutical or implantable device. If subsequent trials maintain these results, the road to clinical adoption could be relatively short.
The team from Aalto University and Helsinki University Hospital has laid a strong foundation. Whether USeFNAB becomes part of standard radiology practice will depend on what the next trials show – but the early signs are genuinely encouraging.
The Bottom Line
Biopsies are a routine part of modern medicine, but their failure rate is anything but routine in its consequences. When a sample comes back inadequate, everything downstream – the diagnosis, the treatment decision, the patient’s peace of mind – is put on hold.
A vibrating needle that collects up to three times more tissue through the same fine-gauge puncture is not a dramatic, headline-grabbing technology. It doesn’t involve artificial intelligence or molecular engineering or gene editing. It’s a precise, practical improvement to a tool that doctors use every day – and that kind of innovation often does more for patients than the flashier breakthroughs that attract more attention.
If subsequent studies hold up, USeFNAB could quietly become one of the most impactful additions to the radiologist’s toolkit in years. Not because of what it can do in theory, but because of what it prevents in practice: the repeat procedure, the second appointment, the anxious wait that shouldn’t have been necessary in the first place.
Source: Naukkarinen M, Le Bourlout Y, et al. “Ultrasound-enhanced fine-needle aspiration biopsy improves yield of solid benign parotid gland tumor tissue: a pilot study.” European Radiology Experimental 10, 41 (2026). DOI: 10.1186/s41747-026-00707-0 | Original coverage: Radiology Business
